Compare DLHC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | XBIT |
|---|---|---|
| Founded | 1969 | 2005 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 71.6M |
| IPO Year | 2012 | 2015 |
| Metric | DLHC | XBIT |
|---|---|---|
| Price | $5.85 | $2.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.6K | ★ 24.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,923,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.57 | N/A |
| 52 Week Low | $2.72 | $2.09 |
| 52 Week High | $8.09 | $3.62 |
| Indicator | DLHC | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 47.18 |
| Support Level | $5.52 | $2.32 |
| Resistance Level | $5.96 | $2.69 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 70.00 | 60.48 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.